Tom Wilbur Tom Wilbur is a director of public affairs at PhRMA focusing on the organization’s federal advocacy priorities including intellectual property and Medicare Part D. Prior to joining PhRMA, Tom worked in national and state politics for nearly a decade, most recently on Capitol Hill as a strategic communicator and campaign manager. Tom is a proud Michigander and in his spare time enjoys reading, live music, and spending time with friends and family cheering on Detroit sports teams.
Recent Posts
IP Explained: What is Section 101 and why reforms are needed
By Tom Wilbur | June 26, 2019
In today’s IP Explained post, we’re taking a closer look at Section 101 of the United States Patent Act and how proposed reforms could both level the playing field for innovators across all...
Read More
The Department of Health and Human Services recently proposed a rule that would encourage using discounts negotiated between biopharmaceutical manufacturers and Part D plans to reduce patients’...
Read More
What you need to know about the CBO rebate rule score
By Tom Wilbur | May 23, 2019
Earlier this year, the Department of Health & Human Services (HHS) Office of Inspector General (OIG) released a proposed rule that takes aim at today’s complex system of list prices and rebates in...
Read More
IP Explained: How Hatch-Waxman successfully balances affordability and innovation
By Tom Wilbur | May 22, 2019
For three decades, The Drug Price Competition and Patent Term Restoration Act, more commonly known as the Hatch-Waxman Act, has fostered innovation, spurred competition and helped the United...
Read More
IP Explained: Myth vs. fact about strong patent protections in the biopharmaceutical industry
By Tom Wilbur | May 2, 2019
Strong patent protections are fundamental to the creation of new treatments and cures that extend and improve patients’ lives. In recent years, critics of the biopharmaceutical industry have...
Read More
IP Explained: What they are saying on the importance of strong intellectual property protections
By Tom Wilbur | April 24, 2019
The U.S. biopharmaceutical industry depends on predictable and reliable intellectual property (IP) protections to maintain its role as the global leader in biopharmaceutical innovation. Strong and...
Read More
IP Explained: Why patents are so critical to biopharmaceutical innovation
By Tom Wilbur | April 16, 2019
Today, we are excited to launch our new IP Explained Catalyst series, where each week we’ll break down critical components of the intellectual property (IP) system and the important role it plays...
Read More
If the six protected classes policy is weakened, the Medicare Part D exception and appeals process will not provide sufficient protections for patients facing access challenges
By Tom Wilbur | March 29, 2019
One of the most important and successful parts of Medicare Part D is the six protected classes policy which covers patients whose conditions – such as HIV, cancer, and epilepsy, among others – are...
Read More
Bipartisan lawmakers urge Administration to rethink proposed changes to six protected classes policy
By Tom Wilbur | March 22, 2019
At the end of 2018, the Centers for Medicare & Medicaid Services (CMS) introduced a dangerous proposed rule that would weaken the Medicare Part D six protected classes policy. The six protected...
Read More
New report: Using march-in authority would jeopardize U.S. innovation
By Tom Wilbur | March 19, 2019
In 1980, Congress passed the Small Business Patent Procedures Act, better known as the Bayh-Dole Act, which created a uniform framework for transferring government-funded research into useful...
Read More
Medicare Monday (100)
340B Spotlight (41)
Cost & Consequence (0)
